🎯
LATEST VERIFIED ALGORITHMIC EXECUTION
Quantitative engine captured a net profit of +19.26% on $OC in just 23h 32m.
CAP
$CAPR
🔒 US EquitiesCapricor Therapeutics, Inc.
AVG HISTORICAL GAP
+8.96%
MAX GAP RECORD
+81.95%
🔒 PRO INSTITUTIONAL
AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡
SENTINEL HISTORICAL GAP VIEWER
// $CAPR
📊 1-YEAR TIMELINE (GAPS PLOTTED)
🔮 SIMULATE SETUP 🔒
GAP INSPECTION // PLAYBACK PROTOCOL
$CAPR
HISTORICAL GAP OCCURRENCE
Analyzing price jump between T-1 close and opening auction.
EVENT DATE—
GAP MAGNITUDE—
T-1 CLOSE—
OPEN PRICE—
AI DIRECTIONPRO ONLY 🔒
Bullish Opening Gap
Bearish Opening Gap
T-1 Close Baseline
CATALYSTS & GAP HISTORY
| Nov 10, 2026 Earnings Release 2026-11-10 (UNDETERMINED) | 🔮 UPCOMING 🔒 |
| Aug 13, 2026 Earnings Release 2026-08-13 (AFTER CLOSE) |
+81.95%
|
| Mar 12, 2026 Earnings Release 2026-03-12 (AFTER CLOSE) |
-1.26%
|
| Nov 10, 2025 Earnings Release 2025-11-10 (AFTER CLOSE) |
+5.94%
|
| Aug 11, 2025 Earnings Release 2025-08-11 (AFTER CLOSE) |
+0.38%
|
| May 13, 2025 Earnings Release 2025-05-13 (AFTER CLOSE) |
+6.03%
|
| Mar 19, 2025 Earnings Release 2025-03-19 (AFTER CLOSE) |
+2.78%
|
| Nov 13, 2024 Earnings Release 2024-11-13 (AFTER CLOSE) |
+0.06%
|
VOLATILITY & GAP BIAS
AVG GAP MOVE
10.3%
Bullish Gaps (6)
Bearish Gaps (2)
Neutral / Flat (4)
📖 Intelligence Summary
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3…
NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗